血脂康胶囊与普伐他汀治疗高胆固醇血症的成本-效果分析  

Application of Cost-effectiveness Analysis in Xuezhikang and Pravastatin forthe Treatment Hypercholesterolemia

作　　者：王大果 李东 聂中越 

机构地区：[1]暨南大学医学院第二附属医院,深圳市人民医院,广东深圳518020

出　　处：《中国药业》2003年第9期53-55,共3页China Pharmaceuticals

摘　　要：目的:探讨血脂康和普伐他汀治疗高胆固醇血症的经济效果。方法:将79例高胆固醇血症患者随机分为两组(血脂康组37例,普伐他汀组42例),用药物经济学方法进行成本-效果分析。结果:总胆固醇(TC)每下降1mmol/L,血脂康和普伐他汀的费用分别是473.02元、642.12元;甘油三酯(TG)每下降1mmol/L,费用分别是2003.38元、6788.21元;低密度脂蛋白胆固醇(LDL-c)每下降1mmol/L,费用分别是490.03元、693.68元;在血脂康疗效的基础上增加一个效果单位,费用分别是100.00元、338.84元。相比而言,血脂康成本-效果低于普伐他汀。结论:药物经济学研究可以弥补临床药物疗效观察研究的不足,在指导合理用药、减轻患者经济负担、提高社会经济效益和指导新药开发方面具有重要作用。Objective:To evaluate the economic effectiveness in the treatment of hypercholesterolemia by Xuezhikang and Pravastatin differently. Methods:79 patients with hypercholesterolemia were randomly divided into two groups.Using pharmacoeconomical cost-effectiveness analysis, Xuezhikang and pravastatin were compared for the treatment of hypercholesterolemia. Results:The cost of Xuezhikang and pravastatin lowering per 1 mmol/L TC were RMB 473.02 yuans and 642.12 yuans , lowering per 1 mmol/L TG were RMB 2 003.38 yuans and 6 788.21 yuans, lowering per 1 mmol/L LDL-c were RMB 490.3 yuans and 693.68 yuans. Xuezhikang was better than pravastatin in lasting treatment for hypercholesterolemia. Conclusion:The results show that pharmacoeconomics is very important in guiding rational drug use and increasing economic effectiveness.

关 键 词：血脂康 普伐他汀 成本-效果分析 高胆固醇血症 药物经济学 

分 类 号：F407.7[经济管理—产业经济] R972.6[医药卫生—药品]